Skip to main navigation
Skip to search
Skip to main content
University of Birmingham Home
Help & FAQ
Link opens in a new tab
Search content at University of Birmingham
Home
Research output
Profiles
Research units
Projects
Activities
Datasets
Equipment
Prizes
Press/Media
Low-dose Btk inhibitors selectively block platelet activation by CLEC-2
Pip Nicolson
, Sophie H Nock
, Joshua Hinds
, Lourdes Garcia Quintanilla
, Christopher Smith
, Joana Campos
,
Alexander Brill
, Jeremy Pike
, Abdullah Khan
,
Natalie Poulter
, Deirdre Kavanagh
, Stephanie Watson
, Callum N Watson
, Hayley Clifford
, Aarnoud Huissoon
, Alice Pollitt
, Johannes A Eble
, Dickens Pratt
,
Steve Watson
, Craig Hughes
Cancer and Genomic Sciences
Cardiovascular Sciences
Immunology and Immunotherapy
Research output
:
Contribution to journal
›
Article
›
peer-review
10
Citations (Scopus)
222
Downloads (Pure)
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Low-dose Btk inhibitors selectively block platelet activation by CLEC-2'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine and Dentistry
Low Drug Dose
100%
Thrombocyte Activation
100%
Ibrutinib
100%
Bruton Tyrosine Kinase Inhibitor
100%
Platelet
75%
Protein Phosphorylation
50%
X Linked Agammaglobulinemia
50%
Inflammatory Disorder
25%
Protein Tyrosine Kinase
25%
Thrombosis
25%
Adenosine Diphosphate
25%
Antiplatelet Drug
25%
Thromboxane A2
25%
Positive Feedback
25%
Thromboxane Receptor
25%
Purinergic P2Y12 Receptor
25%
Acalabrutinib
25%
Biochemistry, Genetics and Molecular Biology
Thrombocyte Activation
100%
Low Drug Dose
100%
Ibrutinib
100%
Platelet
75%
Genitoanal Papilloma Virus Infection
75%
Tyrosine Phosphorylation
50%
Syk
50%
Receptor Tyrosine Kinase
25%
Adenosine Diphosphate
25%
Tyrosine Kinase
25%
Positive Feedback
25%
P2Y12
25%
Thromboxane A2
25%
Thromboxane Receptor
25%
Keyphrases
C-type Lectin-like Receptor 2
100%
Platelet Activation
100%
Ibrutinib
66%
Human Platelets
33%
Tyrosine Phosphorylation
33%
X-linked Agammaglobulinemia
33%
Positive Feedback
16%
Tyrosine Kinase
16%
Inflammatory Diseases
16%
Thrombosis
16%
Differential Effects
16%
Thromboxane A2 (TXA2)
16%
Antiplatelet Agents
16%
P2Y12 Receptor
16%
Mouse Platelets
16%
GPVI Signaling
16%
TP Receptor
16%
Acalabrutinib
16%
Immunology and Microbiology
Platelet
100%
Low Drug Dose
100%
Thrombocyte Activation
100%
Protein Phosphorylation
66%
X-Linked Agammaglobulinemia
66%
Inflammatory Disorder
33%
Positive Feedback
33%
Thromboxane A2
33%
Tyrosine
33%
Pharmacology, Toxicology and Pharmaceutical Science
Ibrutinib
100%
Bruton Tyrosine Kinase Inhibitor
100%
X Linked Agammaglobulinemia
50%
Protein Tyrosine Kinase
25%
Thrombosis
25%
Adenosine Diphosphate
25%
Antithrombocytic Agent
25%
Purinergic P2Y12 Receptor
25%
Inflammatory Disease
25%
Thromboxane A2
25%
Thromboxane Receptor
25%
Acalabrutinib
25%